Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05179538 · ClinicalTrials.gov registry record · NA
Genetic and Cognitive Predictors of Aphasia Treatment Response
A NA study of Aphasia, sponsored by Ohio State University.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT05179538: Active NA study of Aphasia, sponsored by Ohio State University.
NCT05179538 is a NA study of Aphasia that is active but no longer recruiting, run by Ohio State University. The registered enrollment target is 120 participants, above the 81-participant average among 42 other Aphasia trials with a reported enrollment target (48% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05179538, a NA study of Aphasia, is active but no longer recruiting, sponsored by Ohio State University.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
Aphasia, or language impairment after a stroke, affects approximately 2 million people in the United States, with an estimated 180,000 new cases each year. The medical community cannot predict how well someone with aphasia will respond to treatment, as some people with aphasia are poor responders to intervention even when participating in empirically supported treatments. There is a strong likelihood that genetics play a role in language recovery after stroke, but very little research has been dedicated to investigating this link. This study will investigate whether two genes and cognitive abilities, such as memory, predict responsiveness to aphasia therapy for word-retrieval difficulties.
Primary Outcome
Picture-naming score changes from baseline to post-treatment.
Conditions Studied
Interventions
- BEHAVIORAL Cued picture-naming therapy
Study Locations (1)
Ohio
- The Ohio State University - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2020-10-23 |
| Est. Completion | 2026-05 |
| Phase | NA |
What the registry record for NCT05179538 still lists
NCT05179538 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, above the 81-participant average among 42 other Aphasia trials with a reported enrollment target (48% higher).
The record links to 1 condition, with Aphasia appearing as the primary indexed condition, and to 1 intervention - of which Cued picture-naming therapy is the first listed.
NCT05179538 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05179538 about?
NCT05179538 is a clinical study titled "Genetic and Cognitive Predictors of Aphasia Treatment Response". Aphasia, or language impairment after a stroke, affects approximately 2 million people in the United States, with an estimated 180,000 new cases each year. The medical community cannot predict how well someone with aphasia will respond to treatment, as some people with aphasia are poor responders to...
What is the current status of trial NCT05179538?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2020-10-23. Estimated completion is 2026-05.
What conditions does trial NCT05179538 study?
This clinical trial studies the following conditions: Aphasia.
What interventions are being tested in trial NCT05179538?
The interventions under investigation include: Cued picture-naming therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05179538?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05179538 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Aphasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05179538's enrollment target sits among peer trials
120 6th of 42 higher than 33 of 42 other Aphasia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Aphasia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Transcranial Alternating Current Stimulation (tACS) in Aphasia
RECRUITING · NA
-
tACS to Enhance Language Abilities
RECRUITING · NA
-
Treatment Outcomes With tDCS in Post-Stroke Aphasia
RECRUITING · NA
-
Telerehabilitation for Aphasia (TERRA)
RECRUITING · NA
-
Combined Exercise and Targeted Therapy for Post-Stroke Reading Deficits
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI